

# Michel Vallee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4720616/publications.pdf>

Version: 2024-02-01

42  
papers

3,358  
citations

430874

18  
h-index

276875

41  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4410  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.   | 1.7 | 474       |
| 2  | The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.              | 1.7 | 431       |
| 3  | Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588. | 1.7 | 400       |
| 4  | Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.  | 1.7 | 269       |
| 5  | The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.              | 1.7 | 221       |
| 6  | The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.   | 1.7 | 191       |
| 7  | The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.            | 1.7 | 173       |
| 8  | The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 "blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.              | 1.7 | 170       |
| 9  | The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.              | 1.7 | 163       |
| 10 | The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.         | 1.7 | 127       |
| 11 | Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2136-2142.   | 4.5 | 124       |
| 12 | The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.   | 1.7 | 111       |
| 13 | Characterization of UDP-glucuronosyltransferases active on steroid hormones. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 413-423.   | 2.5 | 101       |
| 14 | The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2008, 24, 465-475.   | 1.7 | 78        |
| 15 | The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 "blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2009, 25, 279-286.              | 1.7 | 60        |
| 16 | Outcomes of Infection-Related Hospitalization according to Dialysis Modality. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 817-824.  | 4.5 | 45        |
| 17 | Association of Dialysis Modality with Risk for Infection-Related Hospitalization. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1598-1605.   | 4.5 | 42        |
| 18 | Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center. International Journal of Infectious Diseases, 2012, 16, e41-e43.                               | 3.3 | 31        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Association of Neutrophil-to-Lymphocyte Ratio With Inflammation and Erythropoietin Resistance in Chronic Dialysis Patients. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811773556.             | 1.1 | 15        |
| 20 | Isolation and characterization of the monkey UDP-glucuronosyltransferase cDNA clone monUGT1A01 active on bilirubin and estrogens. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 77, 239-249.      | 2.5 | 14        |
| 21 | Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case-control study. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw268. | 0.7 | 12        |
| 22 | Trends in infection-related hospital admissions and impact of length of time on dialysis among patients on long-term dialysis: a retrospective cohort study. <i>CMAJ Open</i> , 2014, 2, E109-E114.                      | 2.4 | 11        |
| 23 | The 2017 American College of Cardiology/American Heart Association vs Hypertension Canada High Blood Pressure Guidelines and Potential Implications. <i>Canadian Journal of Cardiology</i> , 2018, 34, 665-669.          | 1.7 | 11        |
| 24 | Magnitude of discordance between registry data and death certificate when evaluating leading causes of death in dialysis patients. <i>BMC Medical Research Methodology</i> , 2013, 13, 51.                               | 3.1 | 9         |
| 25 | Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic populations. <i>International Urology and Nephrology</i> , 2009, 41, 983-988.  | 1.4 | 8         |
| 26 | Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients. <i>BMC Nephrology</i> , 2014, 15, 27.  | 1.8 | 8         |
| 27 | Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature. <i>Experimental and Clinical Transplantation</i> , 2014, 12, 323-7.   | 0.5 | 8         |
| 28 | Changes in Urinary and Serum Levels of Novel Biomarkers after Administration of Gadolinium-based Contrast Agents. <i>Biomarker Insights</i> , 2016, 11, BMI.S39199.  | 2.5 | 6         |
| 29 | Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients. <i>International Urology and Nephrology</i> , 2017, 49, 325-328.                  | 1.4 | 6         |
| 30 | Regulation of 21-Hydroxylase activity by steroids. <i>Endocrine Research</i> , 1995, 21, 329-341.  | 1.2 | 5         |
| 31 | Hemodialysis effects on phenytoin pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 499-500.  | 1.9 | 5         |
| 32 | Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021, Volume 14, 301-311.           | 1.8 | 5         |
| 33 | High mortality after pelvis and lower limb fractures in ESRD. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 466-466.  | 2.9 | 4         |
| 34 | The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D. <i>International Urology and Nephrology</i> , 2015, 47, 1165-1171.                                  | 1.4 | 3         |
| 35 | Pharmacokinetic and Dynamic of Furosemide in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2016, 36, 107-108.   | 2.3 | 3         |
| 36 | Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation. <i>Journal of Transplantation</i> , 2017, 2017, 1-6.  | 0.5 | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience. Canadian Journal of Diabetes, 2018, 42, 205-208.  | 0.8 | 3         |
| 38 | The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 989-990. | 0.6 | 3         |
| 39 | Regulation of guinea pig adrenal P450c21 messenger RNA, protein and activity by RU486. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54, 31-38.   | 2.5 | 2         |
| 40 | Difficulty of patient selection in a combined heart-kidney transplant: a case report. Experimental and Clinical Transplantation, 2014, 12, 273-6.  | 0.5 | 2         |
| 41 | Efficacy of calcitriol compared to alfacalcidol for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 895-896.    | 0.6 | 1         |
| 42 | Presumed paradoxical embolus in a patient with diabetic ketoacidosis. International Journal of General Medicine, 2015, 8, 297.   | 1.8 | 0         |